Allogene Therapeutics, Inc.

ALLO · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

–

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders11.0%

Institutions87.6%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$0	$22000	$95000	$243000	$38.49M	–	–	–
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$209.31M	-$273.20M	-$327.74M	-$335.45M	-$255.79M	-$258.24M	-$202.01M	-$192.84M
Operating income as a percentage of revenue.	–	-1241813.6%	-344986.3%	-138044.9%	-664.6%	–	–	–
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$190.89M	-$257.59M	-$327.26M	-$332.63M	-$257.00M	-$250.22M	-$184.59M	-$211.50M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-0.87	$-1.32	$-2.09	$-2.32	$-1.89	$-2.08	$-1.83	$-7.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-0.87	$-1.32	$-2.09	$-2.32	$-1.89	–	–	–

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$51.69M	$75.22M	$83.16M	$61.90M	$173.31M	$183.35M	$175.13M	$92.43M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$415.90M	$548.71M	$642.84M	$817.08M	$1.04B	–	$717.80M	$773.86M
Everything the company owes — debt, unpaid bills, and other obligations.	$123.36M	$126.53M	$130.60M	$151.21M	$122.23M	–	$88.78M	$70.69M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$292.54M	$422.18M	$512.23M	$665.87M	$916.41M	–	$629.02M	$703.16M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$149.25M	-$200.30M	-$237.73M	-$220.52M	-$184.81M	-$115.09M	-$137.35M	-$44.65M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$386000	$694000	$1.52M	$5.19M	$21.45M	$65.96M	$50.79M	$3.23M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$149.63M	-$200.99M	-$239.25M	-$225.71M	-$206.26M	-$181.05M	-$188.14M	-$47.89M

	You	Peer avg
P/E	–	5.4
Revenue Growth	–	+32.6%
ROE	-42.4%	-48.5%

Allogene Therapeutics, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison